# EDGAR Filing Document

**Accession Number:** 0001621221
**File Stem:** 0001640334-25-001747
**Filing Date:** 2025-9
**Character Count:** 5605
**Document Hash:** bde46e7e8a60377887e520c49831ece0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-25-001747.hdr.sgml**: 20250930

**ACCESSION NUMBER**: 0001640334-25-001747

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250930

**DATE AS OF CHANGE**: 20250930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARTELO BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001621221
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 331220924
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-273153
- **FILM NUMBER:** 251358157

**BUSINESS ADDRESS:**
- **STREET 1:** 505 LOMAS SANTA FE, SUITE 160
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
- **BUSINESS PHONE:** 858-925-7049

**MAIL ADDRESS:**
- **STREET 1:** 505 LOMAS SANTA FE, SUITE 160
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REACTIVE MEDICAL INC.
- **DATE OF NAME CHANGE:** 20170207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KNIGHT KNOX DEVELOPMENT CORP.
- **DATE OF NAME CHANGE:** 20141001

**Filed Pursuant to Rule 424(b)(5)**

**Registration No. 333-273153**

 **PROSPECTUS SUPPLEMENT**

(To Prospectus dated July 14, 2023)

**Common Stock**

![](artl_424b5img1.jpg)

This prospectus supplement amends and supplements the information in the prospectus supplement, dated July 18, 2025, as supplemented by that certain prospectus supplement dated September 4, 2025 (as so supplemented, the "ATM Prospectus"), relating to the offer and sale of up to $3,451,527 shares of our common stock, $0.001 par value per share ("Common Stock"), pursuant to the At the Market Offering Agreement between us and R.F. Lafferty & Co., Inc., as exclusive sales agent (who we refer to herein as "Lafferty" or the "Sales Agent"), dated July 18, 2025 (the "Sales Agreement"). This prospectus supplement should be read in conjunction with the ATM Prospectus and the base prospectus, dated July 7, 2023 (the "Base Prospectus"), and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus or the Base Prospectus. This prospectus supplement is not complete without and may only be delivered or utilized in connection with the ATM Prospectus and the Base Prospectus and any future amendments or supplements thereto.

The Common Stock is listed on The Nasdaq Capital Market tier of The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "ARTL." As of September 29, 2025, the last reported sales price of the Common Stock on Nasdaq was $5.85.

We are filing this prospectus supplement to supplement and amend, as of September 30, 2025, the ATM Prospectus and the Base Prospectus, to reduce the maximum aggregate gross sales price of our Common Stock that may be offered, issued, and sold under the Sales Agreement from and after the date hereof to $0 (the "ATM Offering Size Reduction"), as the previously referenced $451,527 of Common Stock has already been sold. Under the ATM Prospectus, we initially registered up to $6,500,000 of our Common Stock for offer and sale pursuant to the Sales Agreement, which amount was then reduced to $3,451,527 on September 4, 2025. As of the date of the filing of this prospectus supplement, we have sold all $451,527 of Common Stock that was available for sale under the ATM Prospectus, and accordingly, no further shares may be offered or sold under the ATM Prospectus unless and until we file another prospectus supplement.

The purpose of this prospectus supplement is to update the ATM Prospectus to reflect the ATM Offering Size Reduction, suspend sales under the Sales Agreement, and to clarify that no further shares may be offered or sold under the ATM Prospectus unless and until we file another prospectus supplement. Except as modified by this prospectus supplement, the terms of the ATM offering remain unchanged, and the Sales Agreement remains in full force and effect.

The aggregate market value of our outstanding shares of Common Stock held by non-affiliates as of September 29, 2025, is $18,399,248, based on 1,555,493 shares of Common Stock outstanding, of which 1,551,370 are held by non-affiliates, and a closing price on Nasdaq of $11.86 on July 31, 2025, which is within 60 days of the date of this prospectus supplement. We are providing this information in accordance with General Instruction I.B.6. of Form S-3. However, as described elsewhere in this prospectus supplement, we have sold all $451,527 of Common Stock that was available for sale under the ATM Prospectus, as supplemented hereby, and as a result, no further shares may be offered or sold under this prospectus supplement unless and until we file another prospectus supplement.

**Investing in our shares of Common Stock involves a high degree of risk and uncertainty. See "Risk Factors" beginning on page S-9 of the ATM Prospectus and the other documents that are incorporated by reference in the ATM Prospectus and the accompanying base prospectus.**

**NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT, THE PRIOR PROSPECTUS SUPPLEMENTS OR THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

**R.F. Lafferty & Co., Inc.**

______________

The date of this prospectus supplement is September 30, 2025.